D
Madrigal Pharmaceuticals, Inc. MDGL
$412.23 -$2.45-0.59% NASDAQ
Recommendation
Prev Close
$412.23
Volume
2
Avg Vol (90D)
370,451
Market Cap
$9.19B
Dividend & Yield
--
52-Week Range
$200.63 - $423.20
P/E (TTM)
--
EPS (TTM)
-$12.85
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Madrigal Pharmaceuticals, Inc. $MDGL is University of Wisconsin Foundation's 3rd Largest Position
8/26/2025 - MarketBeat
TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
8/25/2025 - TipRanks Financial Blog
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?
8/25/2025 - Insider Monkey
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?
8/25/2025 - Yahoo! Finance: News
A Look at Madrigal Pharmaceuticals (MDGL) Valuation After EU Approval Expands Rezdiffra's Market Opportunity
8/25/2025 - Simply Wall St
Candriam S.C.A. Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
8/24/2025 - MarketBeat
Nuveen LLC Buys New Shares in Madrigal Pharmaceuticals, Inc. $MDGL
8/23/2025 - MarketBeat
Cantor Fitzgerald Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)
8/22/2025 - TipRanks Financial Blog
Here's What Made the Artisan Small Cap Fund Reinvest in Wingstop (WING)
8/22/2025 - Insider Monkey
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $485.00 at JMP Securities
8/22/2025 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 7,616 Shares of Stock
8/22/2025 - Zolmax
William John Sibold Sells 7,616 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
8/22/2025 - MarketBeat
B. Riley Brokers Increase Earnings Estimates for MDGL
8/22/2025 - MarketBeat
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues
8/22/2025 - Simply Wall St
American Century Companies Inc. Purchases 21,457 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
8/22/2025 - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
8/21/2025 - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) Announces Equity Awards for New Employees MDGL stock news
8/21/2025 - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule ...
8/21/2025 - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
8/21/2025 - Globe Newswire
Notable Thursday Option Activity: MDGL, ROOT, FWRD
8/21/2025 - Nasdaq News: Markets
Notable Thursday Option Activity: MDGL, ROOT, FWRD
8/21/2025 - Stock Options Channel
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Bros. Advisors Lp Baker Acquires 59,901 Shares
8/21/2025 - Zolmax
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Bros. Advisors Lp Baker Acquires 59,901 Shares
8/21/2025 - MarketBeat
How Investors May Respond To Madrigal Pharmaceuticals (MDGL) Securing First EU Approval for MASH Therapy
8/21/2025 - Simply Wall St
Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 1-Year High - Here's Why
8/21/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$515.55M
EBITDA (TTM)
-$308.40M
EBIT (TTM)
-$309.81M
Net Income (TTM)
-$281.90M
Balance Sheet
Total Assets (Q)
$1.02B
Total Debt (Q)
$123.95M
Total Liabilities (Q)
$319.40M
Book Value Per Share (Q)
$31.32
Cash Flow
Cash from Operations (TTM)
-$307.41M
Cash from Investing (TTM)
-$38.61M
Cash from Financing (TTM)
$37.61M
Net Change in Cash (TTM)
-$308.40M
Filings
Filing Date
Tuesday, August 5, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Oct 27 and 31 (est)
Price History
Loading...
Beta
1.13
7-Day Total Return
11.46%
30-Day Total Return
32.49%
60-Day Total Return
49.76%
90-Day Total Return
33.94%
Year to Date Total Return
31.38%
1-Year Total Return
61.15%
2-Year Total Return
127.97%
3-Year Total Return
488.40%
5-Year Total Return
291.26%
52-week Low
Oct 23, 2024 - $200.63
52-week High
Aug 25, 2025 - $423.20
Valuation
Market Cap
$9.19B - Mid Cap
Enterprise Value
$8.52B
Price/Sales (TTM)
17.76
Price/Book (Q)
13.16
Dividends and Shares
Shares Outstanding
22.21
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.madrigalpharma.com
Phone Number
267 824 2827
Address
Four Tower Bridge
Suite 200 - 200 Barr Harbor Drive
West Conshohocken, PA 19428
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers... more
NASDAQ 08/25/2025 4:00PM Eastern Quotes delayed